BRPI0715718A2 - Anticorpo, métodos de triar para um anticorpo para o domínio extracelular de uma proteína prlr, de alterar sistematicamente anticorpos e triar para um anticorpo para o domínio extracelular de uma proteína prlr, de tratar um indivíduo que sofre de câncer, de alvejar uma célula tumoral que expressa prlr, de usar uma célula hospedeira, de identificar um indivíduo com necessidade de tratamento com um anticorpo anti-prlr, e de monitorar terapia de câncer em um indivíduo, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, composição farmacêutica, e, kit - Google Patents
Anticorpo, métodos de triar para um anticorpo para o domínio extracelular de uma proteína prlr, de alterar sistematicamente anticorpos e triar para um anticorpo para o domínio extracelular de uma proteína prlr, de tratar um indivíduo que sofre de câncer, de alvejar uma célula tumoral que expressa prlr, de usar uma célula hospedeira, de identificar um indivíduo com necessidade de tratamento com um anticorpo anti-prlr, e de monitorar terapia de câncer em um indivíduo, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, composição farmacêutica, e, kitInfo
- Publication number
- BRPI0715718A2 BRPI0715718A2 BRPI0715718-5A2A BRPI0715718A BRPI0715718A2 BR PI0715718 A2 BRPI0715718 A2 BR PI0715718A2 BR PI0715718 A BRPI0715718 A BR PI0715718A BR PI0715718 A2 BRPI0715718 A2 BR PI0715718A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- prlr
- individual
- extracellular domain
- triating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83864806P | 2006-08-18 | 2006-08-18 | |
US94636007P | 2007-06-26 | 2007-06-26 | |
PCT/US2007/076160 WO2008022295A2 (en) | 2006-08-18 | 2007-08-17 | Prlr-specific antibody and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0715718A2 true BRPI0715718A2 (pt) | 2014-06-24 |
Family
ID=39083161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0715718-5A2A BRPI0715718A2 (pt) | 2006-08-18 | 2007-08-17 | Anticorpo, métodos de triar para um anticorpo para o domínio extracelular de uma proteína prlr, de alterar sistematicamente anticorpos e triar para um anticorpo para o domínio extracelular de uma proteína prlr, de tratar um indivíduo que sofre de câncer, de alvejar uma célula tumoral que expressa prlr, de usar uma célula hospedeira, de identificar um indivíduo com necessidade de tratamento com um anticorpo anti-prlr, e de monitorar terapia de câncer em um indivíduo, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, composição farmacêutica, e, kit |
Country Status (38)
Country | Link |
---|---|
US (3) | US7867493B2 (pt) |
EP (4) | EP2059535B1 (pt) |
JP (3) | JP5517619B2 (pt) |
KR (3) | KR20140033241A (pt) |
CN (2) | CN104098699A (pt) |
AR (2) | AR062435A1 (pt) |
AU (1) | AU2007285855B2 (pt) |
BR (1) | BRPI0715718A2 (pt) |
CA (2) | CA2661023C (pt) |
CL (1) | CL2007002412A1 (pt) |
CO (1) | CO6150194A2 (pt) |
CR (1) | CR10612A (pt) |
CU (1) | CU23809A3 (pt) |
CY (1) | CY1114904T1 (pt) |
DK (1) | DK2059535T3 (pt) |
EA (2) | EA017851B1 (pt) |
ES (1) | ES2444065T3 (pt) |
GE (1) | GEP20125612B (pt) |
GT (1) | GT200900035A (pt) |
HK (1) | HK1138603A1 (pt) |
HN (1) | HN2009000379A (pt) |
HR (1) | HRP20140081T1 (pt) |
IL (2) | IL196397A (pt) |
MA (1) | MA30762B1 (pt) |
ME (1) | ME00588A (pt) |
MX (1) | MX2009001829A (pt) |
MY (1) | MY145058A (pt) |
NI (1) | NI200900022A (pt) |
NZ (2) | NZ574138A (pt) |
PE (1) | PE20081214A1 (pt) |
PL (1) | PL2059535T3 (pt) |
PT (1) | PT2059535E (pt) |
RS (1) | RS53092B (pt) |
SI (1) | SI2059535T1 (pt) |
TN (1) | TNSN08548A1 (pt) |
TW (2) | TW201441262A (pt) |
WO (1) | WO2008022295A2 (pt) |
ZA (1) | ZA200900351B (pt) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR062435A1 (es) * | 2006-08-18 | 2008-11-05 | Xoma Technology Ltd | Anticuerpo especifico prlr (receptor de prolactina) y sus usos |
ES2544971T3 (es) * | 2008-05-13 | 2015-09-07 | Genentech, Inc. | Análisis de conjugados de fármacos y anticuerpos mediante espectrometría de masas con captura por afinidad basada en esferas |
ES2788869T3 (es) | 2009-09-03 | 2020-10-23 | Merck Sharp & Dohme | Anticuerpos anti-GITR |
JP5885664B2 (ja) * | 2009-09-25 | 2016-03-15 | ゾーマ テクノロジー リミテッド | スクリーニング法 |
EP2332995A1 (en) | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
RU2600444C2 (ru) | 2010-10-13 | 2016-10-20 | Янссен Байотек, Инк. | Человеческие антитела к онкостатину м и способы их применения |
ES2632486T3 (es) * | 2010-10-18 | 2017-09-13 | Mediapharma S.R.L. | Anticuerpo de unión a ErbB3 |
WO2012136519A1 (en) | 2011-04-06 | 2012-10-11 | Bayer Pharma Aktiengesellschaft | Use of neutralizing prolactin receptor antibodies for the treatment and prevention of antiestrogen-resistant breast cancer |
EP2530089A1 (en) * | 2011-06-03 | 2012-12-05 | Bayer Pharma Aktiengesellschaft | Neutralising prolactin receptor antibody Mat3 and its therapeutical use |
CN102250244A (zh) * | 2011-07-07 | 2011-11-23 | 南京医科大学 | 人源抗人催乳素受体抗体及其应用 |
US9212227B2 (en) | 2012-04-30 | 2015-12-15 | Janssen Biotech, Inc. | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions |
DK2847228T3 (en) | 2012-05-10 | 2018-11-19 | Bayer Pharma AG | ANTIBODIES THAT CAN BIND TO COAGULATION FACTOR XI AND / OR ITS ACTIVATED FORM FACTOR XIA, AND APPLICATIONS THEREOF |
AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
CN102746402A (zh) * | 2012-07-09 | 2012-10-24 | 南京医科大学 | 全人源抗人催乳素受体单链抗体及其应用 |
KR102134088B1 (ko) | 2012-08-24 | 2020-07-14 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신 |
US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
PL2935331T3 (pl) | 2012-12-24 | 2018-07-31 | Abbvie Inc. | Białka wiążące receptor prolaktyny i ich zastosowania |
CA2906101A1 (en) * | 2013-03-15 | 2014-09-18 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗-prlr抗體及其用途 |
FI3088517T3 (fi) * | 2013-12-26 | 2023-11-30 | Mitsubishi Tanabe Pharma Corp | Ihmisen Anti-IL-33 neutraloiva monoklonaalinen vasta-aine |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
EP4218810A3 (en) | 2014-10-02 | 2023-08-09 | City of Hope | Multivalent meditopes, meditope-binding antibodies and uses thereof |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
AU2015333687B2 (en) | 2014-10-14 | 2021-03-18 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to PD-L1 and uses thereof |
EP3233918A1 (en) | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
SG11201706756VA (en) | 2015-03-10 | 2017-09-28 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene" -dependent signalling |
AU2016289480C1 (en) * | 2015-07-06 | 2021-10-21 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
PT3317301T (pt) | 2015-07-29 | 2021-07-09 | Novartis Ag | Terapias de associação compreendendo moléculas de anticorpo contra lag-3 |
CN108697791B (zh) | 2015-11-03 | 2022-08-23 | 詹森生物科技公司 | 特异性结合pd-1的抗体及其用途 |
CN108495651A (zh) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
CN113082201A (zh) | 2016-04-01 | 2021-07-09 | 上海斯丹赛生物技术有限公司 | 刺激t细胞介导的对表达抗原的细胞群的免疫应答的方法 |
US10654934B2 (en) | 2016-04-01 | 2020-05-19 | Innovative Cellular Therapeutics CO., LTD. | Use of chimeric antigen receptor modified cells to treat cancer |
US10188749B2 (en) | 2016-04-14 | 2019-01-29 | Fred Hutchinson Cancer Research Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
EP3474854A4 (en) | 2016-06-27 | 2020-02-19 | The Regents of The University of California | DRUG ASSOCIATIONS FOR THE TREATMENT OF CANCER |
US11098077B2 (en) | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
EP3548514A1 (en) | 2016-11-29 | 2019-10-09 | Regeneron Pharmaceuticals, Inc. | Methods of treating prlr positive breast cancer |
US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
TW201836647A (zh) | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | 抗-prlr抗體藥物軛合物(adc)及其用途 |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
LT3631454T (lt) | 2017-05-30 | 2023-11-27 | Bristol-Myers Squibb Company | Lag-3 atžvilgiu teigiamų navikų gydymas |
AU2018275209A1 (en) | 2017-05-30 | 2019-10-17 | Bristol-Myers Squibb Company | Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody |
EP3642240A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
JP7311514B2 (ja) | 2017-08-30 | 2023-07-19 | ベイジン シュエンイー ファーマサイエンシズ カンパニー, リミテッド | インターフェロン遺伝子刺激因子調節薬としての環状ジヌクレオチド |
WO2019175223A1 (en) | 2018-03-13 | 2019-09-19 | Tusk Therapeutics Ltd | Anti-cd25 for tumour specific cell depletion |
US20210221914A1 (en) * | 2018-05-17 | 2021-07-22 | Immunome, Inc. | Ch3 domain epitope tags |
UY38247A (es) | 2018-05-30 | 2019-12-31 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
CN109627337B (zh) * | 2018-12-29 | 2023-07-21 | 上海复宏汉霖生物技术股份有限公司 | 一种抗prlr的单克隆抗体及其制备方法和应用 |
JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
JP6982129B2 (ja) * | 2020-04-27 | 2021-12-17 | 田中貴金属工業株式会社 | 抗水痘帯状疱疹ウイルス抗体、免疫学的測定方法及び免疫学的測定用装置 |
AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
Family Cites Families (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US30985A (en) | 1860-12-18 | Thomas l | ||
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
GB2056642B (en) | 1979-08-08 | 1983-05-11 | Dawson Int | Radio frequency drying of textile material |
WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
GB2118300B (en) * | 1982-02-12 | 1985-06-19 | Corning Glass Works | Method of immunoassay |
EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US5260203A (en) * | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
DE3889853D1 (de) | 1987-11-05 | 1994-07-07 | Hybritech Inc | Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik. |
US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US4975578A (en) * | 1989-04-17 | 1990-12-04 | The Research Foundation Of State University Of Ny | Method and apparatus for determining distribution of mass density |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
WO1993011266A1 (en) | 1991-12-05 | 1993-06-10 | Sloan-Kettering Institute For Cancer Research | Method for the detection of mutations and monoclonal lineages by analysis of rna conformation polymorphism(s) |
CA2103887C (en) | 1991-12-13 | 2005-08-30 | Gary M. Studnicka | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
DE69333082T2 (de) | 1992-02-11 | 2004-05-06 | Cell Genesys, Inc., Foster City | Erzielen von homozygotem durch zielgerichtete genetische ereignisse |
CA2131151A1 (en) | 1992-03-24 | 1994-09-30 | Kevin S. Johnson | Methods for producing members of specific binding pairs |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
PT752248E (pt) | 1992-11-13 | 2001-01-31 | Idec Pharma Corp | Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b |
US5807549A (en) | 1993-05-21 | 1998-09-15 | Research Corporation Technologies, Inc. | Lymphocyte chemoattractant factor and uses thereof |
WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
US5443953A (en) | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
US6054287A (en) | 1994-05-27 | 2000-04-25 | Methodist Hospital Of Indiana, Inc. | Cell-type-specific methods and devices for the low temperature preservation of the cells of an animal species |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6537776B1 (en) | 1999-06-14 | 2003-03-25 | Diversa Corporation | Synthetic ligation reassembly in directed evolution |
US6489145B1 (en) | 1996-07-09 | 2002-12-03 | Diversa Corporation | Method of DNA shuffling |
CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
GB9712818D0 (en) | 1996-07-08 | 1997-08-20 | Cambridge Antibody Tech | Labelling and selection of specific binding molecules |
CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
US20030044772A1 (en) | 1997-08-04 | 2003-03-06 | Applied Molecular Evolution [Formerly Ixsys] | Methods for identifying ligand specific binding molecules |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
WO2000032634A1 (en) | 1998-12-01 | 2000-06-08 | Protein Design Labs, Inc. | Humanized antibodies to gamma-interferon |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6475220B1 (en) | 1999-10-15 | 2002-11-05 | Whiteside Biomechanics, Inc. | Spinal cable system |
US6406840B1 (en) | 1999-12-17 | 2002-06-18 | Biomosaic Systems, Inc. | Cell arrays and the uses thereof |
US7560534B2 (en) | 2000-05-08 | 2009-07-14 | Celldex Research Corporation | Molecular conjugates comprising human monoclonal antibodies to dendritic cells |
ES2295228T3 (es) | 2000-11-30 | 2008-04-16 | Medarex, Inc. | Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos. |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2002092780A2 (en) | 2001-05-17 | 2002-11-21 | Diversa Corporation | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
US7074175B2 (en) | 2001-07-25 | 2006-07-11 | Erik Schroeder Handy | Thermotherapy via targeted delivery of nanoscale magnetic particles |
US6997863B2 (en) | 2001-07-25 | 2006-02-14 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
US7371849B2 (en) | 2001-09-13 | 2008-05-13 | Institute For Antibodies Co., Ltd. | Methods of constructing camel antibody libraries |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
SI1527100T1 (sl) | 2002-03-29 | 2009-12-31 | Schering Corp | Humana monoklonska protitelesa proti interlevkinu-5 in postopki in sestavki, ki jih obsegajo |
DE60335794D1 (de) | 2002-03-29 | 2011-03-03 | Xoma Technology Ltd | Multigene vectoren und methoden für eine erhöhte expression von rekombinanten polypeptiden |
JP2006512895A (ja) * | 2002-06-28 | 2006-04-20 | ドマンティス リミテッド | リガンド |
EP3476861A1 (en) * | 2004-01-07 | 2019-05-01 | Novartis Vaccines and Diagnostics, Inc. | M-csf-specific monoclonal antibody and uses thereof |
EP1814916A2 (en) * | 2004-11-15 | 2007-08-08 | Eli Lilly And Company | Desacyl ghrelin antibodies and therapeutic uses thereof |
US20060121604A1 (en) | 2004-12-03 | 2006-06-08 | Xoma Technology Ltd. | Methods and materials for expression of a recombinant protein |
EP1871911A2 (en) * | 2005-04-07 | 2008-01-02 | Chiron Corporation | Cancer-related genes (prlr) |
US20070092920A1 (en) * | 2005-10-24 | 2007-04-26 | Clevenger Charles V | Serum Prolactin Binding Protein in Epithelial Carcinoma |
AR062435A1 (es) * | 2006-08-18 | 2008-11-05 | Xoma Technology Ltd | Anticuerpo especifico prlr (receptor de prolactina) y sus usos |
US9545451B2 (en) * | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
TWI641620B (zh) * | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗-prlr抗體及其用途 |
-
2007
- 2007-08-17 AR ARP070103686A patent/AR062435A1/es unknown
- 2007-08-17 EA EA200970210A patent/EA017851B1/ru not_active IP Right Cessation
- 2007-08-17 US US11/840,267 patent/US7867493B2/en active Active
- 2007-08-17 JP JP2009524812A patent/JP5517619B2/ja not_active Expired - Fee Related
- 2007-08-17 KR KR1020147004402A patent/KR20140033241A/ko not_active Application Discontinuation
- 2007-08-17 CN CN201310220338.3A patent/CN104098699A/zh active Pending
- 2007-08-17 NZ NZ574138A patent/NZ574138A/en not_active IP Right Cessation
- 2007-08-17 CA CA2661023A patent/CA2661023C/en not_active Expired - Fee Related
- 2007-08-17 NZ NZ596834A patent/NZ596834A/xx not_active IP Right Cessation
- 2007-08-17 CA CA2932012A patent/CA2932012A1/en not_active Abandoned
- 2007-08-17 EP EP07814191.8A patent/EP2059535B1/en active Active
- 2007-08-17 PE PE2007001114A patent/PE20081214A1/es not_active Application Discontinuation
- 2007-08-17 MY MYPI20090377A patent/MY145058A/en unknown
- 2007-08-17 SI SI200731400T patent/SI2059535T1/sl unknown
- 2007-08-17 GE GEAP200711173A patent/GEP20125612B/en unknown
- 2007-08-17 AU AU2007285855A patent/AU2007285855B2/en not_active Ceased
- 2007-08-17 EP EP18166185.1A patent/EP3415532A1/en not_active Withdrawn
- 2007-08-17 WO PCT/US2007/076160 patent/WO2008022295A2/en active Application Filing
- 2007-08-17 DK DK07814191.8T patent/DK2059535T3/da active
- 2007-08-17 RS RS20130576A patent/RS53092B/en unknown
- 2007-08-17 TW TW103102567A patent/TW201441262A/zh unknown
- 2007-08-17 PT PT78141918T patent/PT2059535E/pt unknown
- 2007-08-17 MX MX2009001829A patent/MX2009001829A/es active IP Right Grant
- 2007-08-17 BR BRPI0715718-5A2A patent/BRPI0715718A2/pt not_active Application Discontinuation
- 2007-08-17 TW TW096130566A patent/TWI454480B/zh not_active IP Right Cessation
- 2007-08-17 KR KR1020137005384A patent/KR101433544B1/ko active IP Right Grant
- 2007-08-17 ES ES07814191.8T patent/ES2444065T3/es active Active
- 2007-08-17 AR ARP070103686D patent/AR064801A1/es unknown
- 2007-08-17 KR KR1020097003942A patent/KR101368596B1/ko active IP Right Grant
- 2007-08-17 CL CL200702412A patent/CL2007002412A1/es unknown
- 2007-08-17 PL PL07814191T patent/PL2059535T3/pl unknown
- 2007-08-17 ME MEP-28/09A patent/ME00588A/xx unknown
- 2007-08-17 EP EP15186855.1A patent/EP3018144A1/en not_active Withdrawn
- 2007-08-17 EA EA201201533A patent/EA201201533A1/ru unknown
- 2007-08-17 CN CN2007800302847A patent/CN101611058B/zh not_active Expired - Fee Related
- 2007-08-17 EP EP11190591A patent/EP2423231A3/en not_active Withdrawn
-
2008
- 2008-12-31 TN TNP2008000548A patent/TNSN08548A1/en unknown
-
2009
- 2009-01-08 IL IL196397A patent/IL196397A/en active IP Right Grant
- 2009-01-15 ZA ZA2009/00351A patent/ZA200900351B/en unknown
- 2009-02-11 CU CU20090021A patent/CU23809A3/es not_active IP Right Cessation
- 2009-02-13 CR CR10612A patent/CR10612A/es unknown
- 2009-02-16 GT GT200900035A patent/GT200900035A/es unknown
- 2009-02-17 NI NI200900022A patent/NI200900022A/es unknown
- 2009-02-18 HN HN2009000379A patent/HN2009000379A/es unknown
- 2009-03-09 MA MA31703A patent/MA30762B1/fr unknown
- 2009-03-17 CO CO09027543A patent/CO6150194A2/es unknown
-
2010
- 2010-04-28 HK HK10104152.4A patent/HK1138603A1/xx not_active IP Right Cessation
- 2010-11-22 US US12/951,744 patent/US9005614B2/en active Active
-
2012
- 2012-12-17 JP JP2012274384A patent/JP2013055959A/ja not_active Withdrawn
-
2013
- 2013-01-17 IL IL224266A patent/IL224266A/en active IP Right Grant
-
2014
- 2014-01-27 HR HRP20140081TT patent/HRP20140081T1/hr unknown
- 2014-01-30 CY CY20141100077T patent/CY1114904T1/el unknown
-
2015
- 2015-03-03 US US14/636,625 patent/US20150175705A1/en not_active Abandoned
-
2016
- 2016-04-01 JP JP2016074116A patent/JP2016130250A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0715718A2 (pt) | Anticorpo, métodos de triar para um anticorpo para o domínio extracelular de uma proteína prlr, de alterar sistematicamente anticorpos e triar para um anticorpo para o domínio extracelular de uma proteína prlr, de tratar um indivíduo que sofre de câncer, de alvejar uma célula tumoral que expressa prlr, de usar uma célula hospedeira, de identificar um indivíduo com necessidade de tratamento com um anticorpo anti-prlr, e de monitorar terapia de câncer em um indivíduo, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, composição farmacêutica, e, kit | |
DE602005000485D1 (de) | Nukleinsäurenachweisverfahren mittels mehreren Paaren von Donorflurophoren und Quenchemolekülen in derselben Sonde | |
BRPI0922350A2 (pt) | anticorpo humano, mólecula biespecífica,vetor de expressão, célula hospedeira eucariótica ou procariótoca recombinante, composição farmacêutica, uso do anticorpo ou da molécula biespecífica, métodos para inibir o desenvolvimento e/ou proliferação de uma célula tumoral que expressa o fator de tecido, para produzir um anticorpo, e para detectar a presença de fator de tecido em uma amostra, composição de diagnóstico, e, kit para detectar a presença de fator de tecido em uma amostra. | |
BRPI0807132A2 (pt) | enzimas para o tratamento de lignocelulósicos, ácidos nucléicos que codificam as mesmas, e metodos e uso das mesmas | |
IL181779A (en) | A group of protein-based medical molecules | |
CL2011002765A1 (es) | Anticuerpo anti-factor de crecimiento nervioso (ngf) con estabilidad in vivo aumentada; vector; celula huesped; metodo de produccion; composicion farmaceutica que lo comprende; kit; y su uso para tratar una enfermedad o afeccion relacionada con ngf. | |
BR112012031071A2 (pt) | 8-proteínas de ligação à il-1 | |
BRPI1013688A8 (pt) | Proteínas de ligação de il-17. | |
BRPI0810744A2 (pt) | Moléculas absorventes de oxigênio, objetos que as contêm, e métodos de sua utilização | |
CL2007001488A1 (es) | Anticuerpo humano o humanizado anti-integrina alfa5beta1; acido nucleico que lo codifica; vector y celula huesped que lo comprenden; procedimiento de produccion; composicion farmaceutica que lo comprende; y su uso para prevenir o tratar trastornos asociados con la integrina. | |
CO6690759A2 (es) | Anticuerpos, fragmentos de unión o derivados de los mismos que se unen específicamente a la proteína 4-1 bb | |
DK2086576T3 (da) | H5-proteiner, nukleinsyremolekyler og vektorer kodende for disse, samt medicinsk anvendelse heraf | |
WO2006044596A3 (en) | Multi-domain amphipathic helical peptides and methods of their use | |
UY31861A (es) | Inmunoglobulina con dominio variable dual y usos de la misma | |
CL2008002444A1 (es) | Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente. | |
DK2195013T3 (da) | Terapeutisk anvendelse af en vækstfaktor, METRNL | |
BRPI1007321A2 (pt) | métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo. | |
BRPI0916624A2 (pt) | anticorpos monoclonais seletivos anti-hepcidina-25, seus usos, bem como método e kit para quantificar a quantidade de proteína hepcidina-25 em uma amostra de tecido ou fluido biológico | |
BR112012030838A2 (pt) | molécula de ácido nucléico isolada que codifica uma proteína mek1 mutante tendo atividade de mek1, vetor de expressão, célula hospedeira, método de produzir uma prote ína mek1 mutante, proteína mek1 mutante isolada, método de identificar um paciente que tem câncer, método de orimizar o tratamento de um paciente que tem câncer,e, uso de um inibidor de raf e de um inibidor de mek. | |
ATE511645T1 (de) | Testverfahren zum nachweis von antikörpern gegen lysosomenenzyme | |
BRPI0719923A2 (pt) | Nucleotídeos e nucleosídeos rotulados fotocliváveis e nucleotídeos e nucleosídeos rotulados e métodos para seu uso no sequenciamento de dna | |
ATE472317T1 (de) | Kosmetische verwendung von molkeproteinmizellen | |
BR112012009846B8 (pt) | método in vitro e kit para detecção de um anticorpo antifármaco de isotipo ige, e uso de um anticorpo antifármaco de isotipo ige no tratamento de distúrbio mediado por ige | |
BRPI0717633A2 (pt) | Anticorpo, composição farmacêutica, e, métodos para detectar uma célula expressando cxcr7 em uma amostra biológica, para tratar, prevenir ou melhorar uma doença e para identificar um modulador de cxcr7 | |
BR112012005670A2 (pt) | ''método para a identificação de um paciente com câncer que pode se beneficiar com a terapia antiagiogênica, método para a predição da responsividade de um paciente com câncer à terapia antiangiogênica, uso de um anticorpo anto- vegf para melhorar o efeito do tratamento de um paciente sofrendo de câncer, método ou uso, kit útil para realizar o método, uso de uma proteína ou usom kit útil para realizar o método, uso de uma proteína ou oligonucleotídeo ou matriz de polinecleotídeo para determinar o nível de expressão de bfgf em um método e kit ou uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |